David Dingli, MD, PhD

In a discussion with Targeted Oncology, David Dingli, MD, PhD, looks at how the use of step-up dosing with tecalistimab helped avoid many serious adverse events.

Discover how the treatment landscape for relapsed/refractory myeloma is evolving through collaboration between academic centers and community oncologists, offering patients access to innovative therapies and clinical trials.

The importance of patient education, remote monitoring, and infection prophylaxis in the safe administration of bispecific antibody therapy for relapsed/refractory multiple myeloma.

David M. Dingli, MD, PhD, discusses the advantages and considerations of CAR T-cell therapy versus bispecific antibodies for relapsed/refractory multiple myeloma, helping patients make informed treatment decisions.

Insights into the use of bispecific antibodies, including talquetamab, and elranatamab, in treating relapsed/refractory multiple myeloma, discussing their efficacy and potential side effects.

Expert perspective on teclistamab, a bispecific antibody, in the context of multiple myeloma treatment, discussing its potential benefits and associated considerations.

An exploration of the landscape of immunologic therapies and alternative approaches for relapsed/refractory multiple myeloma, including bispecific antibodies, XPO1 inhibitors, venetoclax, and more.

David M. Dingli, MD, PhD, a hematologist at Mayo Clinic, as he discusses a challenging case of pentarefractory multiple myeloma in a 76-year-old patient and explores novel treatment options.

The National Comprehensive Cancer Network considers multiple regimens to be acceptable for transplant-eligible patients with a new diagnosis of multiple myeloma. David Dingli, MD discussed the regimens that are currently available for patients.